Phase 3 Heart Failure Trial Size to be Substantially Reduced Following FDA Discussions
Jan 11, 2016 13:00 pm UTC| Business
NEW YORK and MELBOURNE, Australia, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the size of the ongoing Phase 3 trial in chronic heart failure (CHF) of its proprietary...
Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome
Jan 11, 2016 13:00 pm UTC| Business
SAN DIEGO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the...
Varonis Appoints Eric Mann as Chief Operating Officer
Jan 11, 2016 13:00 pm UTC| Business
NEW YORK, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq:VRNS), the leading provider of software solutions for unstructured, human-generated enterprise data, today announced that Eric Mann has joined...
BioXcel and Centrexion Partner to Develop Novel Chronic Pain Therapies
Jan 11, 2016 13:00 pm UTC| Business
BRANFORD, Conn., Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioXcel Corporation, a global leader in developing cloud-based big data platforms and transformative patient treatments, today announced a strategic big data...
Natural Health Trends Announces Fourth Quarter 2015 Estimated Revenue
Jan 11, 2016 13:00 pm UTC| Business
LOS ANGELES, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Natural Health Trends Corp. (NASDAQ:NHTC), a leading direct-selling and e-commerce company that markets premium quality personal care, wellness and "quality of life"...
Aegerion Pharmaceuticals Reports Preliminary 2015 Net Product Sales and Other Business Updates
Jan 11, 2016 13:00 pm UTC| Business
CAMBRIDGE, Mass., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with...
Jan 11, 2016 13:00 pm UTC| Business
SEATTLE, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of...